

**IN THE UNITED STATES DISTRICT COURT  
FOR THE SOUTHERN DISTRICT OF WEST VIRGINIA**

**CHARLESTON DIVISION**

IN RE: COLOPLAST CORP. PELVIC SUPPORT  
SYSTEMS PRODUCTS LIABILITY LITIGATION

MDL 2387

-----  
THIS DOCUMENT RELATES TO CASES  
IDENTIFIED ON EXHIBITS A and B

**PRETRIAL ORDER # 150  
(Docket Control Order – Coloplast Wave 8 Cases)**

The court **ORDERS** that PTO # 149 is **VACATED** because it was dated incorrectly. An identical PTO is attached with the correct date.

The cases on Exhibit A have resided on the inactive docket beginning as early as **July 2, 2017** through **December 31, 2017**. Despite representations in inactive docket orders proposed by the parties and entered by the court, that the cases on Exhibit A have been settled or entered into a settlement model, and despite repeated warnings by the court that cases will not remain on the inactive docket indefinitely, the number of cases on the inactive docket remains in the thousands.<sup>1</sup>

To address this issue, in addition to the court's decision to end the parties' ability to place cases on the inactive docket beginning November 1, 2018 (as accomplished by a previous Pretrial Order), the court finds it necessary to return the cases on Exhibit A to the active docket and place them on the scheduling order set forth below. The cases on Exhibit B

---

<sup>1</sup> The court is aware of pending motions to dismiss in some cases and will deal with them as quickly as possible.

are not flagged as inactive in this MDL and are not currently subject to a docket control order, and the court now enters the scheduling order set forth below as to those cases as well.

Accordingly, the court **ORDERS** that the cases on Exhibits A are:

1. removed from the pending inactive docket; and
2. placed on the active docket.

As to the cases on Exhibits A and B, the court further **ORDERS** that:

1. The cases are *no longer eligible for return to the inactive docket nor may notices of settlement be filed to relieve the parties from scheduling deadlines;*

***2. To the extent other defendants, in addition to Coloplast are named in the cases on Exhibits A and B, the deadlines below also apply to them;***

3. The Clerk will file this Docket Control Order in the main MDL and, as of the time of that filing in the MDL, every case listed on Exhibits A and B (hereinafter referred to as “Wave 8 cases”) becomes subject to the deadlines in this Docket Control Order. This Docket Control Order will be placed in each individual case as quickly as administratively possible; and

4. The following deadlines immediately apply in all Wave 8 cases with ***one important exception. If any of the cases on any exhibit were previously on a docket control order and dispositive and Daubert deadlines had passed before such cases became inactive, the parties may not file or refile dispositive or Daubert motions without first seeking leave of court for good cause shown. While the court is returning cases to the active docket, it is not the court’s intention to allow a new round of pleadings or a second bite at the apple for cases already worked up in previous waves.***

The following deadlines immediately apply in all Wave 8 cases:

**A. SCHEDULING DEADLINES.** The following deadlines shall apply in all Coloplast Wave 8 cases:

Plaintiff Fact Sheets. <sup>2</sup>	02/15/2019
Defendant Fact Sheets. <sup>3</sup>	02/22/2019
Deadline for written discovery requests.	03/25/2019
Expert disclosures served by plaintiffs pursuant to Fed. R. Civ. P. 26 as limited by ¶ 3.a. of this order.	05/24/2019
Expert disclosure served by defendants pursuant to Fed. R. Civ. P. 26 as limited by ¶ 3.a. of this order. <sup>4</sup>	06/24/2019
Expert disclosure served for rebuttal pursuant to Fed. R. Civ. P. 26 as limited by ¶ 3.a. of this order.	07/01/2019
Deposition deadline and close of discovery.	08/01/2019
Filing of dispositive motions.	08/14/2019
Response to dispositive motions.	08/28/2019
Reply to response to dispositive motions.	09/04/2019
Filing of <i>Daubert</i> motions.	08/15/2019
Responses to <i>Daubert</i> motions.	08/29/2019
Reply to response to <i>Daubert</i> motions.	09/05/2019

1. **Completion Date.** The last date to complete depositions shall be the “discovery completion date” by which all discovery shall be completed.

2. **Limitations on Interrogatories, Requests for Admissions and Depositions.** The following limitations apply:

---

<sup>2</sup> The court reminds plaintiffs who have named additional MDL defendants other than Coloplast to serve a defendant-specific Plaintiff Fact Sheet as required in that particular defendant’s MDL.

<sup>3</sup> Where plaintiffs have named multiple defendants (i.e., C. R. Bard, Inc., and Ethicon, Inc., Boston Scientific Corp., etc.), each defendant must serve a Defendant Fact Sheet using the form agreed to in that defendant’s MDL.

<sup>4</sup> Paragraph 3.a. of this order states the “the plaintiffs and each defendant are limited to no more than five (5) experts per case (exclusive of treating physicians).”

- a. Each defendant<sup>5</sup> is limited to 10 interrogatories, 10 requests for production of documents and 10 requests for admission per case.
- b. Plaintiffs are limited to 10 interrogatories, 10 requests for production of documents and 10 requests for admission to each defendant.
- c. In each individual member case, no more than 4 treating physicians may be deposed.<sup>6</sup>
- d. Depositions of plaintiff's friends and family members may be taken at any time prior to trial provided the deposition is requested before the discovery completion date.
- e. The Deposition of any witness is limited to 3 hours absent agreement of the parties.
- f. The court will consider modifications to the above limitations only upon good cause shown.

3. **Limitations on Experts.** The following limitations related to experts apply:

- a. The parties may conduct general and specific expert discovery on all products at issue in this Wave. In light of the products involved in this Wave, the likelihood of overlap in expert opinion from one case to another (except as to specific causation) and the need to streamline discovery in

---

<sup>5</sup> In referring to the "defendant" or "defendants" throughout this order, it is my intention that a defendant(s) includes the defendant and its related entities, i.e., Ethicon, Inc. and Johnson & Johnson are related entities and treated as one defendant for purposes of these discovery limitations. Likewise, if more than one plaintiff is named, plaintiffs are treated as one entity for purposes of these discovery limitations.

<sup>6</sup> To the extent disputes arise regarding the division of time between the parties for the deposition of treating physicians (three hours total absent agreement), I will address those disputes, rather than the assigned Magistrate Judge, Judge Eifert.

these cases, **the plaintiffs and each defendant are limited to no more than five experts per case (exclusive of treating physicians).**

- b. The parties shall coordinate the depositions of general causation experts. Insofar as multiple plaintiffs or multiple defendants use the same general causation expert or experts or general causation rebuttal experts, those experts shall be deposed only once on the issue of general causation. As to defendants' experts, plaintiffs are instructed to choose a lead questioner.
- c. The court encourages the coordination of depositions of specific causation experts to the extent there is overlap in the parties' use of specific causation experts by multiple parties.
- d. The court will consider modifications to the above limitations only upon good cause shown.

**4. Transferring to another MDL, requesting removal from the Wave and extensions of deadlines.**

- a. *Transfer of any case from this wave to any other MDL, whether by ruling upon a motion from plaintiff or defendants or sua sponte by the court, does not relieve the plaintiff or any remaining defendant(s) from the deadlines of this Docket Control Order.*
- b. If an Amended Short Form Complaint properly filed pursuant to Federal Rules of Civil Procedure 15(a), names a new party, then any party may move for an extension to the Docket Control Order.

## **B. MOTION PRACTICE.**

1. **Daubert Motions.** For the filing of *Daubert* motions on general causation issues only, the parties are instructed to file one *Daubert* motion per expert in the main MDL (MDL 2387) instead of the individual member case.<sup>7</sup> Each side may file one response and one reply in the main MDL to each *Daubert* motion. This limitation does not apply to specific causation *Daubert* motions, responses and replies. Specific causation *Daubert* motions, responses and replies must be filed in the individual member cases. To the extent a challenged expert is both a general and specific causation expert, the parties must file a general causation motion in the main MDL 2387 and an individual specific causation motion in an individual member case.

2. **Page Limitations.** The page limitations provided in Local Civil Rule 7.1(a)(2) apply to memoranda in support of all dispositive and *Daubert* motions, oppositions, and replies. The court will not consider pleadings that exceed these limitations.

3. **Confidential Documents.** In the past, the court has permitted parties to file placeholder exhibits in support of *Daubert*, dispositive and other motions, responses and replies in the place of confidential documents that may be sealed and then, within five days, redact/dedesignate the documents or file a motion to seal. *The court will no longer permit this practice. Parties may no longer file placeholder exhibits.* The court expects leadership counsel for plaintiffs and defendants to resolve

---

<sup>7</sup> If parties wish to adopt previous *Daubert* motions on general causation experts from other MDLs, they may file a notice of adoption with a copy of the previous filing (if necessary) they wish to adopt in the main MDL 2387.

issues related to confidential designations well before the filing of motions. In the event there are issues related to sealing of confidential documents that the parties are unable to resolve, they must be brought to the court's attention in a consolidated manner as follows: Any consolidated motion to seal is due on or before **June 27, 2019**, and any response is due by **July 11, 2019**. Any reply is due by **July 18, 2019**. The court expects full compliance with Local Civil Rule 26.4(c).

4. **Locations of Filings.** With the exception of the general causation *Daubert* motions as outlined above, the parties are reminded that they must file dispositive and *Daubert* motions on specific causation, responses and replies in the applicable member cases only, not in the Coloplast MDL.

#### **C. CASES READY FOR TRANSFER, REMAND OR TRIAL**

1. **Venue Recommendations.** By no later than **July 8, 2019**, the parties shall meet and confer concerning the appropriate venue for each of the cases, and the parties are **ORDERED** to submit joint venue recommendations to the court by **July 15, 2019**. The parties' joint recommendation(s) shall identify cases where venue is in dispute. The court may then request briefing.

2. **Transfer and Remand.** The court, pursuant to PTO # 10 and 28 U.S.C. § 1404(a), will transfer each directly-filed case to a federal district court of proper venue as defined in 28 U.S.C. § 1391. In the alternative, pursuant to PTO # 10 and 28 U.S.C. § 1407, cases that were transferred to this court by the MDL Panel

shall be remanded for further proceedings to the federal district court from which each such case was initially transferred.<sup>8</sup>

3. **Trial Settings.** If a case is to be tried in the United States District Court for the Southern District of West Virginia (either by agreement of the parties or where venue in the Southern District is determined to be proper by the court), the case shall be deemed trial-ready when discovery is completed and the court rules on the parties' summary judgment motions. The trial date for cases transferred or remanded to other federal district courts shall be set by the judge to whom the transferred or remanded case is assigned (including the undersigned through intercourt assignment).

**D. COMMON BENEFIT TIME.** I have entered a number of Pretrial Orders related to the eventual recovery of the cost of special services performed and expenses incurred by participating counsel in this and the other MDLs assigned to me. I direct the parties' attention to PTO # 6<sup>9</sup>, and its warning that "[n]o time spent on developing or processing purely individual issues in any case for an individual client (claimant) will be considered or should be submitted, nor will time spent on any unauthorized work." Pretrial Order No. 6, ECF No. 15, ¶ C. The court is of the opinion it is highly unlikely that any work performed by counsel on individual wave cases will be considered common benefit work.

---


<sup>8</sup> As expressly contemplated by PTO # 10, Coloplast does not waive its right to seek transfer—pursuant to 28 U.S.C. § 1406(a) or any other available ground—of any case to a court of proper venue, regardless of whether that case was transferred to or directly-filed in the Southern District of West Virginia. I entered identical PTOs in the remaining MDLs assigned to me.

<sup>9</sup> I entered identical PTOs in the remaining MDLs assigned to me.



The court **DIRECTS** the Clerk to file a copy of this order in 2:12-md-2387 **and in the Coloplast Wave 8 cases identified on Exhibits A and B**. It shall be the responsibility of the parties to review and abide by all pretrial orders previously entered by the court. The orders may be accessed through the CM/ECF system or the court's website at [www.wvsd.uscourts.gov](http://www.wvsd.uscourts.gov).

ENTER: February 5, 2019



JOSEPH R. GOODWIN  
UNITED STATES DISTRICT JUDGE

**EXHIBIT A**

<b>Civil Action No.</b>	<b>Case Name</b>
2:12-cv-05021	Williams v. Mentor Worldwide LLC et al
2:13-cv-05957	Haddix v. Mentor Worldwide LLC et al
2:13-cv-18743	Hoke v. Coloplast Corp.
2:14-cv-04188	Green et al v. Mentor Worldwide LLC et al

## EXHIBIT B

<b>Civil Action No.</b>	<b>Case Name</b>
2:18-cv-01006	Armstead et al v. Coloplast Corp.